Livisto Boflox Flavour (Boflox) flavoured tablets 80 mg for dogs . Composition Each tablet contains: Active ingredient: Marbofloxacin 80 mg Pharmaceutical form Oblong beige tablets with brown spots, with a dividing line on both sides. The tablets can be divided in half. Detailed clinical data Target animal species: dogs. Indications for specific target animal species Treatment of infections caused by marbrofloxacin-susceptible strains of microorganisms.
urinary tract infections, associated or not associated with prostatitis or epididymitis
respiratory tract infections.
Contraindications : Do not use marbofloxacin in dogs less than 12 months of age, and in large breed dogs with a longer growth period such as Great Dane, Briard, Bernese Mountain Dog, Bouvier and Mastiff, do not use in dogs under 18 months of age. Do not use in cases of hypersensitivity to fluoroquinolones or to any of the excipients of the product. Do not use in cases of quinolone resistance, as there is (almost) complete cross-resistance between quinolones and other fluoroquinolones. The medicinal product is not suitable for the treatment of infections caused by strictly anaerobic bacteria, yeasts or fungi. Do not use in cats. 20 mg tablets with a score line are available for the treatment of this species. Specific warnings for each target animal species: Urine with low pH may inhibit the action of marbofloxacin. Special precautions for use Fluoroquinolones have been shown to cause damage to articular cartilage in growing dogs and therefore care should be taken with dosage, especially when used in young animals. Neurological side effects of fluoroquinolones are also known. They should be used with caution in dogs with known epilepsy. Fluoroquinolones should be reserved for the treatment of diseases that have responded poorly, or are expected to respond poorly, to treatment with other classes of antibacterial agents. Whenever possible, fluoroquinolone therapy should be based on susceptibility testing. Use of the product deviating from the recommendations given in the SPC may increase the incidence of fluoroquinolone-resistant bacteria and may decrease the effectiveness of treatment with other quinolones due to the potential for cross-resistance. Official and local antibiotic policy recommendations should be followed when using the product. Precautions Special precautions to be taken by the person administering the veterinary medicinal product to animals: People with known hypersensitivity to (fluoro)quinolones should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician. Wash hands after use. Adverse reactions (frequency and severity) At the recommended therapeutic doses, there should be no side effects in dogs. In particular, no joint damage was observed at the recommended doses. However, joint pain and/or neurological symptoms (ataxia, aggressive behavior, convulsions, depression, etc.) rarely occur. Allergic reactions (transient skin reactions) associated with possible histamine secretion have been observed. Mild side effects such as vomiting, loose stools, increased thirst and transient agitation may occasionally occur. These symptoms resolve spontaneously after treatment and do not require discontinuation of treatment. The frequency of adverse reactions is presented according to the following rule:
very common (more than 1 in 10 animals displaying activity (a) undesirable during one course of treatment)
common (more than 1 but less than 10 per 100 animals).
uncommon (more than 1 but less than 10 per 1000 animals).
rare (more than 1 but less than 10 per 10,000 animals).
very rare (less than 1 in 10,000 animals, including individual reports).
Studies in pregnant rats and rabbits have shown no adverse effects during pregnancy. However, no specific tests have been performed in pregnant dogs. For use in pregnant and lactating animals only after a benefit/risk assessment by a veterinarian. Interaction with other medicinal products or other forms of interaction Fluoroquinolones are known to interact with orally administered cations (aluminum, calcium, magnesium, iron). In such cases, bioavailability may be reduced. Do not use antibiotics in combination with tetracyclines and macrolides due to possible antagonistic effects. With simultaneous use with theophylline, the half-life and plasma concentration increase. Therefore, the dose of theophylline should be reduced. Dosage and administration The recommended dose is 2 mg/kg once daily.
Dogs (duration of treatment, days) : skin and soft tissue infections (skin fold dysfunction, impetigo, folliculitis, furunculosis, cellulitis) -from 5 to 40 days; urinary tract infections, associated or not associated with prostatitis or epididymitis -from 7 to 28 days; respiratory tract infections -from 7 to 21 days
Cats (duration of treatment, days) : skin and soft tissue infections (skin fold dysfunction, impetigo, folliculitis, furunculosis, cellulitis) -from 3 to 5 days; respiratory tract infections -up to5 days, administered once daily. To ensure correct dosing (avoiding low doses), the animal's weight should be accurately determined. The tablets can be divided along the score line to facilitate accurate dosing.
Duration of treatment In the case of skin and soft tissue infections, the treatment period is at least 5 days. Depending on the course of the disease, the treatment may be extended to 40 days. In the case of urinary tract infections, the treatment period is at least 10 days. Depending on the course of the disease, the treatment may be extended to 28 days. In the treatment of respiratory tract infections, the treatment period is at least 7 days. Depending on the course of the disease, the treatment may be extended to 21 days. Overdose Overdose may cause damage to articular cartilage and acute symptoms in the form of neurological disorders (e.g. drooling, watery eyes, chills, myoclonus, seizures), which should be treated symptomatically. Withdrawal period(s): Not applicable Pharmaceutical data List of excipients: lactose monohydrate, cellulose powder, povidone, crospovidone, colloidal anhydrous silicon dioxide, calcium behanate, yeast beef. Pharmaceutical incompatibility: Not applicable. Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life of tablets divided into halves: 4 days. Special precautions for storage No special precautions regarding temperature storage of the medicinal product. Store blisters in the original packaging. If tablets have been divided, the remaining halves should be stored in the blister cavity. Any divided tablets stored for more than 4 days should be discarded. Детальніше: https://zoovetbaza.com.ua/ua/p847506817-bofloks-marbofloksatsin-20mg.html